Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. (Q38478296)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

main subject

cost–benefit analysis

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

H Grabowski

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 August 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

Social Science and Medicine

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

535-544

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

Does expenditure on pharmaceuticals give good value for money?: current evidence and policy implications

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

Medicaid patients' access to new drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

Returns to R&D on new drug introductions in the 1980s

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

US Medicaid drug formularies: do they work?

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

https://api.crossref.org/works/10.1016%2FS0277-9536%2896%2900394-2

7 January 2021

10.1016/S0277-9536(96)00394-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9226779%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference